BMY Stock Falls 0.89% Despite Robust Pumitamig Trial Results Traded at 244th in 460 Million Dollar Volume

On September 8, 2025, , ranking 244th in the market. The stock’s performance followed the release of interim Phase 2 trial data for pumitamig, a PD-L1xVEGF-A bispecific antibody co-developed with BioNTech. . These results, presented at the IASLC World Conference, support ongoing Phase 3 ROSETTA LUNG-01 trials and highlight pumitamig’s potential to redefine first-line treatment for this aggressive cancer type.

The data, consistent with earlier Chinese trials, . Bristol’s partnership with BioNTech aims to address unmet needs in oncology, with pumitamig currently in over 20 global trials across 10 solid tumor indications. The Orphan Drug designation from the FDA in 2025 further underscores its therapeutic potential. However, the stock’s modest decline suggests market skepticism about near-term commercialization timelines, given the drug’s Phase 3 status and the competitive landscape in .

Backtest results for the strategy: To set this up rigorously, clarify the market universe (e.g., S&P 500), ranking execution timing (open vs. close), price conventions, and frictional cost assumptions. A benchmark like the S&P 500 TR can be included for comparison. Once parameters are defined, .